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Abstract
Background: There is good evidence that trauma-focused therapies for Post-Traumatic Stress Disorder are effective.
However, they are not always feasible to deliver due a shortage of trained therapists and demands on the patient. An
online trauma-focused Guided Self-Help (GSH) programme which could overcome these barriers has shown promise in
a pilot study. This study will be the first to evaluate GSH against standard face-to-face therapy to assess its suitability for
use in the NHS.
Methods: The study is a large-scale multi-centre pragmatic randomised controlled non-inferiority trial, with assessors
masked to treatment allocation. One hundred and ninety-two participants will be randomly allocated to receive either
face-to-face trauma-focused cognitive behaviour therapy (TFCBT) or trauma-focused online guided self-help (GSH). The
primary outcome will be the severity of symptoms of PTSD over the previous week as measured by the Clinician
Administered PTSD Scale for DSM5 (CAPS-5) at 16 weeks post-randomisation. Secondary outcome measures include
PTSD symptoms over the previous month as measured by the CAPS-5 at 52 weeks plus the Impact of Event Scale –
revised (IES-R), Work and Social Adjustment Scale (WSAS), Patient Health Questionnaire-9 (PHQ-9), General Anxiety
Disorder-7 (GAD-7), Alcohol Use Disorders Test (AUDIT-O), Multidimensional Scale for Perceived Social Support (MSPSS),
short Post-Traumatic Cognitions Inventory (PTCI), Insomnia Severity Index (ISI) and General Self Efficacy Scale (GSES)
measured at 16 and 52 weeks post-randomisation. Changes in health-related quality of life will be measured by the
EQ-5D and the level of healthcare resource utilisation for health economic analysis will be determined by an amended
version of the Client Socio-Demographic and Service Receipt Inventory European Version. The Client Satisfaction
Questionnaire (CSQ) will be collected at 16 weeks post-randomisation to evaluate treatment satisfaction.
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Discussion: This study will be the first to compare online GSH with usual face-to-face therapy for PTSD. The strengths
are that it will test a rigorously developed intervention in a real world setting to inform NHS commissioning.
The potential challenges of delivering such a pragmatic study may include participant recruitment, retention
and adherence, therapist retention, and fidelity of intervention delivery.
Trial registration: ISRCTN13697710 registered on 20/12/2016.
Keywords: PTSD, Post-traumatic stress disorder, RCT, Randomised controlled trial, Guided self-help, Trauma
focused, Intervention, Internet, Online, Protocol
Background
Post-Traumatic Stress Disorder (PTSD) is a common
mental disorder that may develop following exposure to
exceptionally threatening or horrifying events. Charac-
teristic symptoms include persistent intrusive recollec-
tions, avoidance of trauma-related stimuli, negative
alterations in thoughts and mood and hyper-arousal [1,
2]. About 3% of the adult population suffer from current
PTSD [3] and average symptom duration is normally
prolonged in those who are untreated [4]. PTSD is asso-
ciated with substantial co-morbidity [4–8] and signifi-
cant economic burden [9, 10].
A number of psychological approaches have been de-
veloped to treat PTSD. Evidence suggests that the most
effective approaches are trauma focused cognitive behav-
ioural therapy (TFCBT), including trauma focused cog-
nitive therapy, and eye movement desensitization and
reprocessing therapy (EMDR) [11]. TFCBT typically in-
volves some degree of structured exposure to and pro-
cessing of traumatic memories and trauma reminders,
alongside cognitive restructuring of dysfunctional beliefs
about the meaning of the trauma. EMDR is a psycho-
logical therapy that involves exposure to unwanted and
distressing memories whilst focusing on a bilateral
stimulation. TFCBT and EMDR have become the treat-
ments of choice for PTSD, recommended by clinical
guidelines in the UK and internationally [12–14].
TFCBT protocols vary in the focus on exposure or cog-
nitive interventions and differ slightly in the number of
treatment sessions that are recommended. National In-
stitute for Health and Care Excellence (NICE) recom-
mend treatment of 8–12 sessions lasting 60–90 min for
individuals who have experienced a single trauma, with
a recommendation of more than 12 sessions in chronic,
complex cases i.e. with multiple traumas.
Despite a growing consensus that trauma focused psy-
chological therapies (TFPTs) represent the most effective
way of treating PTSD, they are not always feasible to
deliver. There remains a shortage of suitably qualified
therapists to deliver these interventions and therefore, in
many places, lengthy waiting times are common. If left
untreated, PTSD is associated with functional and emo-
tional impairment, reduced quality of life, a predisposition
for the development of other psychiatric and physical ill-
nesses, increased suicidal ideation, higher healthcare util-
isation, and higher rates of alcohol abuse and dependence
[15–21]. Current TFPT treatment requires a considerable
commitment from the service user to attend weekly out-
patient appointments on a regular basis over several
months. Therapy can be difficult for some people to
access, due to factors such as perceived stigma about
attending mental health services, difficulty getting time off
work, problems accessing or arranging suitable childcare
and travel for people living in remote areas [22–24]. As a
result of these and other factors, drop-out from TFPT
interventions can be high [11].
Guided self-help (GSH) could offer a solution to these
issues. GSH combines the use of self-help materials (e.g.,
a work-book, or a website), with regular guidance from a
trained mental health professional and requires less ther-
apist time than an equivalent therapist-administered
treatment. There is good evidence of the efficacy of GSH
in other mental health disorders [25]. In recognition of
these findings NICE recommended that a randomised
controlled trial (RCT) of GSH should be conducted to
assess the efficacy and cost-effectiveness of guided self-
help compared with trauma focused psychological inter-
ventions for mild and moderate PTSD [12]. If effective,
GSH would offer a time-efficient treatment option with
the potential to reduce waiting times and would be more
accessible and less of a burden to participants. It is also
likely that GSH would reduce intervention costs, and
may lessen the burden of PTSD to the NHS and society.
Some of the authors (JB, CL, NR, NK) have systemat-
ically developed a novel, internet-based GSH programme
for PTSD based on TFCBT. This was developed over a
number of years following Medical Research Council
(MRC) guidance for the development of a complex
intervention [26] with significant input from PTSD suf-
ferers and professional stakeholders. Intervention devel-
opment work was completed between 2007 and 2010. A
modelling phase included key stakeholders in focus
groups and semi-structured interviews to inform the
content, delivery and guidance of a GSH programme for
PTSD. Data was analysed using qualitative methodology
and used to inform the first prototype. The prototype
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was piloted twice with a total of 19 participants with
PTSD and refined on the basis of qualitative and
quantitative results. Quantitative results strongly sup-
ported the potential of the programme to effectively
treat PTSD [27].
An interactive online version of the programme was
produced through a Knowledge Transfer Partnership
(KTP) between Health Care Learning Limited Ltd (HCL)
and Cardiff University. The partnership combined HCL’s
expertise in developing high quality internet-based pro-
grammes, with the academic team’s experience of devel-
oping and evaluating psychological interventions for
PTSD. A pilot feasibility RCT of the intervention was
completed between 2012 and 2014. Forty-two partici-
pants with mild to moderate PTSD after a single trau-
matic event were randomised to receive immediate GSH
or delayed treatment [28].
Following GSH, PTSD sufferers’ symptoms improved
by over 50% (completers only) and over 40% (intention
to treat) with an average of 149 min of therapist input;
effect sizes that compare favourably with those found for
therapist-delivered TFPT. The treatment group had sig-
nificantly lower levels of traumatic stress symptoms, de-
pression, anxiety and functional impairment at post-
treatment and one month follow-up, in comparison to
the delayed treatment group, who improved to the same
degree after receiving GSH for PTSD. Results of the
development and pilot work indicated a strong rationale
for conducting a larger scale RCT to determine whether
GSH represents a treatment option that should be
routinely used in the care of PTSD sufferers, as it is for
depression and numerous anxiety disorders.
A Cochrane review of RCTs of online GSH for PTSD
in comparison to face-to-face therapy, waitlist or usual
care [29] found two previous studies [30, 31]. The first
compared online GSH with 104 min of guidance to a
waitlist in 42 adults with PTSD [30]. A large within
group effect size was found in the GSH group from pre-
to post-treatment for self-reported PTSD symptoms
(Cohen’s d = 1.18) but a smaller between groups effect
size was found post-treatment, due to symptom im-
provement in the control group. The second RCT com-
pared online GSH to a delayed treatment minimal
attention group in 62 PTSD sufferers [31]. A larger be-
tween group effect size of d = 1.25 was found. The inter-
ventions included in both studies were largely text-based
and may not have been optimal in terms of usability.
The online GSH intervention developed by this study
team includes audio and video clips and is therefore
more interactive which may explain the positive results
seen in the pilot study.
The review demonstrated that there have been no
comparative trials of online GSH and face-to-face ther-
apy to date, precluding firm decisions being made on
whether to deliver GSH for PTSD as an alternative to
face-to-face therapy in the NHS. The proposed study
will address this by generating high quality scientific evi-
dence for an intervention already developed by us
through state of the art methodology. Our aim is to test
online GSH as a treatment for adults who have been ex-
posed to a single traumatic event. The primary objective
of the trial is to determine: Whether an online TFCBT
based GSH programme is not inferior to individual
TFCBT for patients with PTSD as judged by reduced
symptoms of PTSD at 16 weeks post-randomisation,
thus enabling decisions to be made about its suitability
for use in the NHS. The secondary objectives of the trial
are to determine:
1. Whether an online TFCBT based GSH programme
is not inferior to individual TFCBT for patients with
PTSD as judged by reduced symptoms of PTSD at
52 weeks post-randomisation.
2. Whether an online TFCBT based GSH programme
is not inferior in effectiveness to individual TFCBT
for patients with PTSD as judged by improved quality
of life at 16 weeks and 52 weeks post-randomisation.
3. The impact of an online TFCBT based GSH
programme on functioning, symptoms of depression,
symptoms of anxiety, symptoms of PTSD, alcohol
use, insomnia, perceived social support, self-efficacy
and cognitions for people with PTSD at 16 weeks
and 52 weeks post-randomisation.
4. Whether an online TFCBT based GSH programme
is cost-effective relative to individual TFCBT for
patients with PTSD at 16 weeks and 52 weeks
post-randomisation.
5. The factors which may impact effectiveness and
successful roll-out of online GSH for PTSD in the
NHS if the GSH programme is shown to be effective.
Methods/design
The design is that of a multi-centre pragmatic rando-
mised controlled non-inferiority trial with assessors
masked to treatment allocation. Individual randomisa-
tion will be used.
Study setting
The trial will take place in NHS Improving Access to
Psychological Therapy (IAPT) services based in primary
care in England, and in NHS psychological treatment
settings based in primary and secondary care in Scotland
and Wales. The sites cover urban and rural, economic-
ally and non-economically deprived areas of the UK in
Coventry, Warwickshire, Greater Manchester, London,
South West Yorkshire, South Wales and Lothian.
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Eligibility criteria
Wide eligibility criteria will be used to ensure good ex-
ternal validity. Given the high rate of co-morbidity of
PTSD and other conditions such as depression and sub-
stance misuse, individuals with co-morbidity will be in-
cluded if they satisfy the other inclusion/exclusion
criteria and PTSD is considered the primary diagnosis.
This is consistent with NICE guidance for the treatment
of PTSD [12] and will result in a pragmatic trial. See
Table 1 for Inclusion and Exclusion Criteria.
With reference to inclusion criterion 2, previous work
with more complex and severe forms of PTSD, e.g. fol-
lowing prolonged and repeated trauma suggests that it
often requires increased therapist time and is therefore
less likely to be effectively treated by GSH [12]. In terms
of criterion 5, symptoms can remit when monitored,
hence the 2 week self-monitoring period in which partic-
ipants will be asked to complete a simple daily diary of
symptoms at home [32, 33]. Participants cannot engage
in concurrent psychological therapy whilst in the trial.
They can continue taking psychotropic medication but
are not eligible if they have had a change in medication
4 weeks prior to being assessed.
Interventions
The trial will compare online GSH against individual
face-to-face TFCBT, which is current standard care in
the sites taking part in the trial.
TFCBT for PTSD
TFCBT for PTSD is one of the standard treatments
adopted by IAPT in England and has been shown to be
effective in RCTs in England [11, 33–36] and Northern
Ireland [37]. There are a number of evidence based
TFCBTs and, given the pragmatic nature of the trial, it
will be permissible to use any one of them with individ-
uals allocated to the TFCBT arm. An example of an
evidence-based TFCBT is cognitive therapy for PTSD
(CT-PTSD). CT-PTSD involves identifying the relevant
appraisals, memory characteristics, triggers, and behav-
ioural and cognitive strategies that maintain PTSD
symptoms. CT-PTSD addresses these symptoms by: 1)
Modifying excessively negative appraisals of the trauma
and/ or its sequelae, 2) Reducing re-experiencing by
elaboration of the trauma memories and discrimination
of triggers, 3) Dropping dysfunctional behaviours and
cognitive strategies, particularly those related to avoid-
ance of triggers for intrusive symptoms. These are strat-
egies that have the immediate aim of reducing one’s
sense of current threat but have the long-term effect of
maintaining the disorder, and are common in PTSD.
In this study, TFCBT will be delivered by experienced
psychological therapists currently working in the IAPT
or psychological services. They come from a variety of
backgrounds, including mental health nurses, clinical
psychologists and counsellors, and have varying levels of
experience in working therapeutically with people with
PTSD. All therapists will attend at least 1 one-day work-
shop on one of the TFCBT programmes. In addition, all
study therapists are required to attend at least one and a
half days training in CT-PTSD delivered by the group
who developed CT-PTSD and to be assessed as being at
least satisfactorily competent in the delivery of TFCBT
by one of the two supervising authors who are experi-
enced in TFCBT (NK, NR). The therapists will be given
a treatment manual and will receive supervision once
per month from one of two authors (NK, NR).
TFCBT will be delivered face-to-face to individual par-
ticipants over the course of up to 12 sessions, each last-
ing 60–90 min. Appointments will take place at the
service base. In-session treatment is augmented by daily
homework assignments which participants are required
to complete between sessions. They will be asked to
complete the Impact of Events Scale-Revised (IES-R) at
each session to measure and monitor their PTSD
symptoms.
Spring: An internet based guided self-help Programme for
PTSD
Spring is an online GSH programme based on TFCBT.
It uses the same principles as TFCBT but aims to reduce
contact time with the therapist by providing some of the
therapy content and activities in an accessible self-help
Table 1 RAPID Inclusion and Exclusion Criteria
Inclusion Criteria
Participants must be:
1) Aged 18 or over
2) Screen positive for PTSD to a single traumatic event on the Trauma
Screening Questionnaire (TSQ)
3) Have regular access to the internet in order to complete the steps
and homework required by the GSH programme
4) Be willing and able to give informed consent to take part
5) After a 2 week monitoring period, continue to meet CAPS-5 criteria
for mild to moderate PTSD (score less than 50)
6) Have PTSD as their primary diagnosis.
Exclusion Criteria
A person is not eligible to enter the trial if any of the following apply (all of
these are measured via self-report):
1) Inability to read and write fluently in English
2) Previous completion of a course of TFPT for PTSD
3) Currently engaged in a psychological therapy
4) Change in psychotropic medication in the last 4 weeks
5) Psychosis
6) Substance dependence
7) Active suicide risk
Nollett et al. BMC Psychiatry  (2018) 18:77 Page 4 of 14
format. Potential advantages include that the service
user can engage in the intervention at a time and place
convenient to them which may reduce drop out, and it
may also reduce waiting list times as it should reduce
the input time required for therapist.
The expectation is that Spring will be delivered by the
same therapists delivering the TFCBT. All the therapists
will receive a half day’s training from two of the authors
who were involved in developing the intervention and
delivering it in the pilot study (NK, NR). Therapists also
receive ongoing supervision of one or more training
cases until they are regarded as competent. The thera-
pists will work from a manual and, for the duration of
the trial, will receive supervision once per month from
NK or NR.
Spring is an 8 week online program comprising eight
steps (see Table 2. Spring PTSD Steps).
The therapist initially meets with the participant at the
service base for an hour to develop a rapport, learn
about the participant’s trauma and describe the
programme, which the participant then completes online
in their own time. There are four subsequent fortnightly
meetings of 30 min, normally undertaken face-to-face,
but potentially deliverable via the internet or telephone,
according to participant preference. The participant will
also receive four brief telephone calls or email contact
between sessions to discuss progress, identify any prob-
lems that have arisen and sometimes set new goals. The
modules are accompanied by homework. At each ses-
sion, the therapist reviews progress by logging into a
clinician dashboard, and guides the participant through
the programme. The aim of the guidance is to offer con-
tinued support, monitoring, motivation and problem
solving. The eight online steps are usually completed in
turn with some later steps relying on mastery of tech-
niques taught in earlier steps. Each step provides
psycho-education and the rationale for specific compo-
nents of treatment. Each step activates a tool that be-
comes live in the Toolkit area of the website and aims to
reduce traumatic stress symptoms. Everything entered
into the Toolkit becomes visible (with the participant’s
knowledge) to the therapist via the dashboard to facili-
tate input. The programme can be accessed online via a
web browser or through an App. Participants will be
able to use their PCs, tablets or smart phones to engage
with the programme. A screenshot taken from Step 1
can be seen in Fig. 1: Spring Screenshot. Participants will
be asked to complete the IES-R at each face-to-face ses-
sion to measure and monitor their PTSD symptoms.
Participant withdrawal
A participant may withdraw or be withdrawn from ei-
ther intervention for the following reasons: 1) With-
drawal of consent to participate in the intervention by
the participant, 2) Any alteration in the participant’s
condition which justifies the discontinuation of the
intervention in the therapist’s/Principal Investigator’s
opinion. For example, developing a condition which
would exclude them from the study based on the eligi-
bility criteria.
In the case of suicidal ideation, the therapist will assess
the participant to determine whether or not they can
continue or need to be referred elsewhere. In the case
that a participant scores 50+ on the CAPS-5 at follow-
up, they will also need to be assessed by the clinical
team and may be offered additional treatment. Partici-
pants who solely withdraw/are withdrawn from the
intervention will continue in follow-up unless they with-
draw their consent for this.
Participants can chose to withdraw from the trial
intervention, withdraw from follow-up, withdraw from
both aspects, or withdraw from both aspects and ask
that previously collected data not be used.
Fidelity
To ensure the interventions are delivered as intended
and according to the manuals, each therapist will aim to
audio record at least one session with every participant
using a digital recorder (however, this may not be prag-
matic for GSH if the sessions are solely conducted on
the telephone or by email). The audio recordings will be
rated using a general and an intervention specific fidelity
checklist by one of two independent raters, who have re-
ceived training in the intervention. We will record the
number of sessions attended or missed for each partici-
pant, and the time spent on the GSH programme to
measure adherence.
Table 2 Spring PTSD Steps
Step 1: Learning About My PTSD – Psychoeducation about PTSD
illustrated by four actors describing their experience of PTSD to
different types of traumatic event.
Step 2: Grounding Myself - Explanation of grounding and its uses along
with descriptions and demonstrations of grounding exercises.
Step 3: Managing My Anxiety – Education about relaxation techniques
with learning through videos of a controlled breathing technique, deep
muscular relaxation and relaxation through imagery.
Step 4: Reclaiming My Life – Behavioural re-activation to help individuals
return to previously undertaken/new activities.
Step 5: Coming to Terms with My Trauma – Provides rationale for imaginal
exposure, narratives of the four video characters. The therapist helps the
participant to begin writing a narrative, which they complete remotely and
read every day for at least 30 min.
Step 6: Changing My Thoughts – Cognitive techniques to address PTSD
symptoms.
Step 7: Overcoming My Avoidance – Graded real life exposure work.
Step 8: Keeping Myself Well – This session reinforces what has been learnt
during the programme, provides relapse prevention measures and
guidance on what to do if symptoms return.
Nollett et al. BMC Psychiatry  (2018) 18:77 Page 5 of 14
Outcomes
The primary outcome will be the severity of symptoms
of PTSD over the previous week as measured by the
Clinician Administered PTSD Scale for DSM5 (CAPS-5)
[38] at 16 weeks post-randomisation. The CAPS-5 is a
30 item structured interview for assessing PTSD diag-
nostic status and symptom severity. It is the gold stand-
ard in PTSD assessment and can be used to make a
current (past month) or lifetime diagnosis of PTSD or to
assess symptoms over the past week. Items correspond
to the DSM5 criteria for PTSD. Previous versions of the
CAPS have excellent reliability and convergent and dis-
criminant validity, diagnostic utility, and sensitivity to
clinical change [39]. Sixteen weeks was chosen as a post-
intervention measurement.
Secondary outcomes include the severity of PTSD
symptoms at 52 weeks post-randomisation to determine
whether any effects of the intervention are sustained,
and will be measured using the CAPS-5 1 month ver-
sion. Other secondary outcomes to be measured at both
16 weeks (to determine the effect of the intervention)
and 52 weeks post-randomisation (to determine sus-
tained effects) will include symptoms known to be com-
monly associated with PTSD along with functional
status. To assess these, we will use self-report measures
that are routinely collected by IAPT services: 1) Trau-
matic stress as measured by the Impact of Event Scale –
revised [40], 2) Quality of Life/functional impairment as
measured by the Work and Social Adjustment Scale
[41], 3) Depression measured by the Patient Health
Questionnaire-9 [42], 4) Anxiety measured by General
Anxiety Disorder-7 [43] and 5) Alcohol use measured
by AUDIT-O [44].
Additional, non-IAPT measures will be administered
at 16 and 52 weeks post-randomisation. Perceived social
support will be measured using the Multidimensional
Scale for Perceived Social Support [45], and the level of
healthcare resource utilisation for health economic ana-
lysis will be determined by an amended version of the
Client Socio-Demographic and Service Receipt Inventory
European Version [46]. Changes in health related quality
of life will be measured by the EQ-5D [47] and changes
in sleep measured by the Insomnia Severity Index [48].
A short version of the Post-Traumatic Cognitions
Inventory [49] and the General Self Efficacy Scale [50]
will be collected to determine effects on cognitions and
self-efficacy respectively. The Client Satisfaction Ques-
tionnaire [51] will be collected at 16 weeks post-
randomisation only, to evaluate treatment satisfaction.
The IES-R will be collected at each therapy contact to
provide clinical feedback and also to facilitate imput-
ation for missing data, if required. How frequently it is
collected will depend on the frequency of therapist con-
tact, but is likely to be weekly in the TFCBT arm and
fortnightly in the GSH arm.
Process evaluation
A process evaluation conducted alongside the main trial
will explore contextual factors and mechanisms of
change that may impact on effectiveness and successful
rollout of the intervention post-trial. Specifically, we will
examine the contextual factors surrounding intervention
delivery, which will include assessment of recruitment,
retention, fidelity and adherence. The process evaluation
will be developed according to the MRC guidance [52]
and will make use of both quantitative data (including
Fig. 1 Spring Screenshot. A screenshot, taken from Step 1, showing the actors whose PTSD case histories are followed throughout the intervention. The
Toolkit can be seen at the bottom of the webpage
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fidelity measurement, retention, adherence rates, time
spent on different steps of the GSH programme) and
qualitative data from interviews with therapists and par-
ticipants pre- and post-intervention. Detailed informa-
tion regarding whether the intervention was delivered as
intended (fidelity) and the quantity of the intervention
implemented (dose) will allow us to test the theorised
mechanism of effect of GSH for PTSD (a combination
of: psycho-education about PTSD; imaginal and in-vivo
exposure work to achieve habituation to distressing im-
ages and avoided situations; cognitive work to identify
and modify negative/distorted cognitions; and stress
management skills to cope with anxiety and other symp-
toms) and whether certain factors appear to be more
important than others.
Sample size
As the study aims to demonstrate non-inferiority of
GSH for PTSD compared to TFCBT, the power calcula-
tion considers the non-inferiority margin as opposed to
the effect size. The non-inferiority margin will be 5
points on the 80 point CAPS-5 scale. A recent meta-
analysis [11] indicates that the standardised mean differ-
ence between TFCBT and waitlist/usual care for the
treatment of PTSD is − 1.62. This corresponds to 16.6
points on the CAPS-5. This means that if we demon-
strate non-inferiority to within 5 points of the gold
standard, we will also demonstrate superiority over wait
list/usual care in line with International Conference on
Harmonisation Harmonised Tripartite Guideline (Statis-
tical Principles for Clinical Trials) E9 (ICH E9) guidance
for non-inferiority studies [53, 54].
Pilot work indicates an intraclass correlation coefficient
of 5.6% at the therapist level at 10 weeks. At 22 weeks,
however, there was no observable clustering of CAPS-5
scores amongst therapists. Given our primary outcome
(CAPS-5) is measured at 16 weeks we have allowed for
1% clustering and recalculated the sample size. We have
allowed for 20% attrition. On the basis of the anticipated
average therapist cluster size being four, the design effect
is 1.03, requiring a 3% inflation of the sample size. This re-
sults in a final sample size of 192 (inflated from 186)
which provides 90% power (nQuery v7.0).
For the qualitative elements of the study, the sample
size will be guided by preliminary analysis and constant
comparison (comparing and contrasting themes from
other interviews) during each data collection phase, until
the research team is satisfied that there is data saturation
and no new themes which are important to the research
question arise [55]. However, it is helpful to have a guide
to sample size for study planning. Based on previous re-
search [56] we propose that interviews will be conducted
with 10–20 participants and 8 therapists purposefully
sampled from the different geographical sites.
Recruitment
Please refer to Fig. 2: Participant Timeline, for partici-
pant activity throughout the study. Prospective partici-
pants will be identified through Primary Care Mental
Health Services (PCMHS) in South Wales, through
IAPT services in England and psychological treatment
services in Scotland. Three centres in Cardiff, Manches-
ter and Musselburgh will initially oversee recruitment at
up to 3 sites each and one site in London. More sites
may be added if necessary. Primary care and other rele-
vant workers in these services will be educated about the
study and the eligibility criteria, and asked to identify
and refer patients who may be experiencing PTSD to a
single traumatic event and meet two of the other eligibil-
ity criteria (aged 18+ with regular access to the internet).
They will be provided with a Summary Information
sheet of the study, which they can discuss with the pa-
tient. With the patient’s consent, they will pass their
contact details to the researchers by secure fax or a tele-
phone call. The researcher will then telephone the pa-
tient to confirm they are over 18 years old with regular
internet access, screen positive for PTSD on the Trauma
Screening Questionnaire (TSQ) and do not appear to
meet any of the exclusion criteria. If the patient is prob-
ably eligible, the researcher will send them a copy of the
Participant Information Booklet to read before the ap-
pointment. If the patient is found to be ineligible, they
will be referred back to the referring service. The refer-
ring services will be contacted regularly and will be pro-
vided with trial branded merchandise such as pens to
remind them about the study.
If necessary, to obtain the number of participants re-
quired, the Cardiff centre may also recruit participants
through the National Centre for Mental Health (NCMH)
cohort of participant volunteers. The cohort of over
9500 participants with lived experience of a mental ill-
ness currently includes 890 individuals with a diagnosis
of PTSD, the majority of whom live in South Wales. A
member of the NCMH team would contact potentially
eligible individuals who have consented to being con-
tacted about future research, to screen for eligibility and
invite participation if eligible.
In addition to the methods described above, individ-
uals referred to the local tertiary traumatic stress ser-
vices will be screened by service clinicians and details of
potentially eligible patients passed to the research team
as described above. Information about the study will be
communicated across all primary and secondary care
services (including counselling services) in the recruit-
ment areas and University Student Support Services
(these were a source of recruitment in the pilot study).
A limited number of leaflets will be available at key NHS
services such as IAPT services, GP surgeries, Accident
and Emergency services and outpatient clinics. We will
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publicise the trial publicly in conjunction with the
NCMH communications team. This will include targeted
press releases to local media with the offer of an inter-
view with one of the study team, news items and adver-
tisements on the NCMH website (www.ncmh.info), and
a social media campaign to raise awareness of the study.
We will seek to explore opportunities to recruit through
the Criminal Justice System by linking with Victim Sup-
port, Sexual Assault Referral Centres (SARCs) and HM
Court Services.
A screening log of all ineligible and eligible but not
consented/not approached will be kept at each site so
that any biases from differential recruitment will be
detected.
Allocation and blinding
Where possible, baseline measures will be collected elec-
tronically using an online database. Following comple-
tion of the baseline assessment, the database will inform
the assessor that the participant is eligible for random-
isation and the assessor will click the ‘Randomise Partici-
pant’ button. The database will allocate the participant
to either GSH or TFCBT using pre-programmed soft-
ware. This information will not be available to the asses-
sor, who is blind to allocation, instead the database will
email the trial manager who will inform the appropriate
therapist. Individual randomisation will be conducted
using an online minimisation algorithm generated by the
trial statistician. The ratio will be 1:1. Minimisation will
Fig. 2 Participant Timeline. Participant activity throughout the trial
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ensure balance between trial arms for gender, but will
retain a random element and will be stratified by
research centre.
It is not possible to blind the therapists or the partici-
pants given the complex interventions under investiga-
tion. However, the outcome assessors will be blind to
treatment allocation and the therapists and participants
will be asked not to discuss their allocation with the as-
sessor. This will be stressed at the start of the interview
and will minimise any potential bias the assessor may
have when conducting the outcome assessments. To
measure the success or otherwise of allocation conceal-
ment, the assessors will be asked to guess the partici-
pant’s allocation before and after each assessment. This
will be recorded and compared to chance at the end of
the study.
Data Collection Methods & Data Management
All assessments will be conducted by research assessors
who are either employed as Research Assistants by the
centres involved, or are Clinical Studies Officers from
the local Clinical Research Network. They will all receive
training in rating the outcome measures. For the CAPS-
5, this includes at least 1 day full training followed by
rating a recording of an interview between an actor and
an experienced interviewer. Assessors could be signed
off if they score within 10% of the total score agreed by
two of the authors (JB, CL), score differently on a max-
imum of four items and do not score more than one
point different on any individual item. In order to ensure
accurate ratings, assessors will receive video CAPS-5 in-
terviews every 6 months to rate and return to JB and CL
who will provide feedback.
Once they receive a referral, assessors will contact the
potential participant by telephone to conduct a screen-
ing questionnaire made up of the TSQ and simple ques-
tions to assess inclusion criteria 1–3 and all of the
exclusion criteria. Eligible participants will be sent a Par-
ticipant Information Booklet and a daily diary and will
be asked to monitor their symptoms for 2 weeks, as pre-
vious studies have found that this results in significant
reduction in symptoms for some PTSD sufferers [33].
After the 2 week monitoring period, those still inter-
ested in taking part will be asked to attend a face-to-face
appointment. Assessors, who have been trained in Good
Clinical Practice (GCP) and receiving informed consent,
will begin the consent process with the participant by
reading through the Patient Information Booklet to-
gether and giving them to time to ask questions about
the study. The assessor will then ask the participant to
complete the triplicate study Consent Form if they are
happy to do so. One copy will be given to the participant
to keep. The assessor will then conduct the baseline as-
sessment, which will assess inclusion criteria 4–6 and
re-check criteria 2 (single event) and exclusion criteria 7.
They will collect demographic data and the outcome
measures previously outlined. Follow-up assessments
will occur, as close as possible, to 16 weeks and 52 weeks
post-randomisation. This will involve re-administration
of the outcome measures and may be conducted face-
to-face or on the telephone.
To improve data quality and completeness we have
developed a study specific online database which can be
accessed by all of the assessors. During the assessments,
participants are encouraged to complete the self-report
questionnaires directly onto the computer and assessors
also complete the remaining parts of the interview
online. The database flags up any missing variables, or
entries outside the permissible range, thus ensuring
complete and accurate data. Access to the database will
be restricted to named study personnel only via a secure
login and password. The system will be roles-based with
restricted read/write/edit permissions. Any changes
made to the data will be stored in the audit log within
the system’s database with a full history of changes being
recorded. The system will be accessible via any online
PC, tablet or mobile device. Data will be stored securely
on a secure server. In case of lack of access to an inter-
net connection, we also have back-up paper case report
forms which are entered onto the database as soon as
possible. When paper copies are used, a copy will be
sent to the trial co-ordinating centre and the data en-
tered will be verified.
Qualitative interviews will be conducted with a sample
of participants once they have consented to the trial but
ideally prior to starting the intervention, and then again
after the intervention. A sample of therapists will also be
interviewed prior to commencing delivery of the inter-
ventions and again on completion. All interviews will be
digitally audio-recorded then transcribed by a member
of the study team.
To aid retention, participants will be offered a £10
shopping voucher on completion of the 16 week and
52 week follow-up assessments as a token of appreci-
ation for their participation in the study. Where a par-
ticipant wishes to withdraw from the intervention, their
participation in the follow-up assessments will be
encouraged. Unless a participant has withdrawn consent
for follow-up, repeated attempts using different
approaches will be made to contact participants who
cannot be easily contacted. In a step-wise manner, this
will involve checking contact details with their study
therapist, calling the individual on all contact numbers
provided on various days of the week and at different
times, sending emails and a letter to the addresses pro-
vided. If contact can still not be made, the individual’s
GP will be contacted to check contact details are correct.
If these attempts do not result in contact being made
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within 1 month of loss of contact or the planned follow-
up, a letter will be sent asking the participant to re-
establish contact if they are able to and advising that
they will be contacted again at the next follow-up point
unless they advise otherwise. For any participant reluc-
tant to complete the full outcome assessment at follow-
up we will attempt to gain the CAPS-5 information as a
minimum dataset. As much information as possible will
be collected from protocol non-adherers, with a mini-
mum of the primary and secondary outcome measures
and reasons for non-adherence.
Statistical methods
The primary analysis will be performed using analysis of
covariance, predicting follow-up CAPS-5 score control-
ling for baseline CAPS-5 score and important patient
characteristics (including all minimisation variables).
This will be a complete case intention to treat analysis.
Checks will be made to ensure there is no appreciable
clustering of outcomes within therapists, but if such
clustering exists the primary analysis will be hierarchical.
The results will be summarised using point estimates,
95% confidence intervals and p-values. Since this is a
non-inferiority design, we will be checking whether the
confidence interval for the difference between arms lies
entirely within the 5 point non-inferiority margin. Partic-
ipants with missing CAPS-5 score at follow-up will have
a CAPS-5 score estimated from available IES-R scores
(this will involve building a prediction model using in-
formation from participants with both IES-R and CAPS-
5 scores). We will explore differences in treatment
effects by gender in a sub-group analysis by including an
interaction term between treatment arm and gender.
A sensitivity analysis will use multiple imputation to
account for missing data if the number of cases lost due
to incomplete information exceeds 10%. Secondary out-
comes include: CAPS-5 at 52 weeks, IES-R, WSAS,
PHQ-9, GAD-7, AUDIT-O, MSPSS, EQ-5D, ISI, GSES,
PTCI, adapted CSSRI-EU and CSQ-8. These are all con-
tinuous measures and will be analysed similarly to the
primary outcome. Transformations will be explored to
improve model fit if distributional assumptions are not
satisfied. This will be assessed by visual inspection and
formal fit statistics compared to decide on the trans-
formation chosen.
IES-R scores over time will be explored using a hier-
archical modelling (including clustering by therapist if
this is identified in the primary analysis) and an appro-
priate covariance structure allowing for IES-R scores
within an individual to be correlated over time. Covari-
ance structures to be explored include autoregressive
terms (AR), moving average (MA), and combined terms
(ARMA). This will facilitate the fitting of IES-R trajec-
tories over time (since randomisation) interacted with
intervention arm, whilst also controlling for the same
covariates as the primary analysis. A sensitivity analysis
will use multiple imputation to account for missing data
if the number of cases lost due to incomplete informa-
tion exceeds 10%. A further sensitivity analysis will ac-
count for patient adherence to the protocol using
complier adjusted causal effect (CACE) analysis [57]. All
analyses will be performed in the R programming lan-
guage and environment or SPSS [58, 59].
Qualitative data will be analysed using framework ana-
lysis [60]. This is a systematic five-stage method, which
is increasingly being used in health care research [61]. It
will allow us to compare themes across time point, treat-
ment centre, and interviewee category (i.e. patient and
therapist). We will identify contradictory data, as points
of contrast as well as similarities will be important in
order to understand uptake of the GSH tool. The
method is well defined and allows for greater transpar-
ency. Vital measures will be put into place to ensure val-
idity and reliability. More than one person will be
involved in the analysis and double coding will be car-
ried out until consensus is reached. The framework ana-
lytic approach has been selected as it is a recognised
transparent analytic approach. This qualitative compo-
nent has been designed using the principles of the Crit-
ical Appraisal Skills Programme qualitative checklist, to
ensure the quality of qualitative research [62].
Health economics
An economic evaluation will be conducted from the per-
spective of the UK NHS and personal, social services. To
determine the cost-effectiveness of GSH versus CBT for
PTSD, and the extent to which it can be regarded as
representing value for money, two analyses will be under-
taken – one will assess the relative cost-effectiveness by
estimating the incremental costs of achieving changes in
natural units of outcome that commissioners, health care
professionals, public health decision makers and service
users find relevant (e.g. incremental cost of achieving a
percentage improvement in PTSD symptoms as measured
by CAPS5). The second analysis will use the EQ-5D util-
ities for a cost utility analysis estimating the incremental
costs per quality adjusted life year (QALY) gained. The
QALY gains will also be used in a net–benefit analysis
based on accepted NICE ‘value for money’ thresholds.
The contributions associated with the GSH in relation
to staff time and costs associated with training of thera-
pists, along with materials and equipment used in the
process associated with GSH development and imple-
mentation, will be collected during the trial by inter-
views with relevant finance staff, logged in physical units
and translated into costs using published unit costs [e.g.
[63, 64]. Resource utilisation of services prior to the
GSH implementation, as a result of the intervention,
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and at follow-up relative to the control group, will be
measured using the CSSRI-EU.
As the follow-up is at 52 weeks, no costs and outcomes
will be subjected to discounting. Uncertainty around the
cost and effectiveness estimates will be investigated by:
probabilistic sensitivity analysis, using the incremental
cost per QALY as the metric for this assessment measured
against the NICE range of ‘willingness to pay’ thresholds
between £20 k and £30 k per incremental QALY gained
represented by cost-effectiveness acceptability curves [65].
a series of one-way sensitivity analyses to assess the im-
pact of parameter variation on baseline estimates of the
range of incremental cost-effectiveness ratios; and a set of
alternative scenarios will be constructed, based on the
findings from relevant studies of CBT for PTSD [33, 35–
37] to compare the relative cost-effectiveness of GSH
against different durations of CBT and supportive care .
In addition to a trial-based analysis, longer-term cost-
effectiveness will be assessed using decision analytic
modelling methods. The derived model, based on a
review of published models at the time of the analysis,
will use parameter estimates derived from the trial and
information from literature sources relating to long-term
effects of PTSD, alongside other sources, to arrive at
meaningful long-term estimates of cost-effectiveness and
budget impact.
Trial monitoring
The trial will be monitored by a Trial Steering Commit-
tee (TSC) made up of independent members including
lay members who will meet annually. We will also form
a Data Monitoring Committee again made up of mem-
bers independent of the trial. There are currently no
planned interim analyses or stopping criteria.
All Serious Adverse Events (SAEs) must be reported
immediately (and within 24 h of knowledge of the event)
to the co-ordinating centre’s safety team. In addition to
the usual SAE categories, for the purposes of this trial
severe self-harm and harm to others must be reported.
Therapists will be asked to notify the study team directly
should they be concerned at any time that a participant
has caused, or is likely to cause, significant harm to
themselves. The therapist should also inform the partici-
pant’s GP. Therapists will be asked to inform the appro-
priate authorities directly should they become concerned
at any time that a participant has, or is likely to cause
significant harm to others. Assessors will be asked to
complete a brief risk assessment if the participant dis-
closes suicidal ideation and should discuss with a mem-
ber of the clinical team what action to take.
Screening, recruitment, withdrawal and SAEs will be
centrally monitored on a weekly basis. Database valida-
tions will be checked every 2 months and all consent
forms received at the site will be checked. Following any
amendments to the protocol or associated documents,
the sites will be sent new versions and asked to con-
firm receipt. Their confirmation will be recorded on
the relevant log. On site monitoring will occur only if
a visit is triggered, for example, repeated protocol or
GCP breaches.
Data protection and indemnity
All personnel involved in the trial will act to preserve
participant confidentiality and will not disclose or repro-
duce any information by which participants could be
identified, except where specific consent is obtained.
Data will be stored in a secure manner and will be regis-
tered in accordance with the Data Protection Act 1998.
The data custodian and the translational sample custo-
dian for this trial is Cardiff University. The Trial Man-
ager, the Database Programmer and Statistician will have
access to the final dataset.
Where participants are recruited at NHS sites the
NHS indemnity scheme/NHS professional indemnity
will apply with respect to claims arising from harm to
participants at site management organisations.
Dissemination
Trial findings will be disseminated widely using a variety
of tailored methods targeting specific audiences. A sum-
mary report of trial results written in lay language will
be sent to study participants and other key stakeholders.
The report will also be displayed and available at venues
used for recruitment. We will hold informal patient-
centred meetings at each trial site, to present the results
orally and allow time for questions and clarification. We
will also hold an open conference at each centre in the
final month of the project. If the outcome is positive, the
conferences will include free training in the GSH
programme for NHS staff coupled with free access to
the programme for a certain number of therapeutic en-
counters. We will send reports of trial results to NHS
commissioners, outlining the cost-saving potential of
GSH if applicable and the scope for improving routine
clinical practice for PTSD. We will disseminate the find-
ings publicly through news items on the NCMH website
(www.ncmh.info), which attracts an average of 2250
unique visitors each month, and an article in the widely
circulated NCMH newsletter.
We will publicise the trial results through social media
and publish posts related to trial progress and results on
the NCMH blog-site. This site features posts that have
attracted up to 10,000 hits. We have experience of
successfully engaging local and national media and will
work with the NCMH communications team to formu-
late strategies for press releases and the dissemination of
findings through newspaper articles and radio features.
We will work with knowledge brokers, such as the
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Science Media Centre, to maximise coverage. Study out-
comes will be presented to the academic community at
national and international conferences by means of oral
presentation, poster presentation, and interactive work-
shops. We will target conferences likely to be attended
by large numbers of therapists and managers working in
IAPT and other primary and secondary care NHS psy-
chological treatment services. We will also disseminate
to the third sector and other services likely to deal with
individuals with PTSD who could potentially benefit
from treatment (e.g. SARCs, Victim Support). We aim to
publish the quantitative, qualitative and health economic
results in high impact, open-access, peer reviewed jour-
nals. A complete account of the research will also be
published in the NIHR HTA Journal.
All the dissemination and promotion activities will be
supported by project specific webpages on the NCMH
website. The webpages will include descriptions of the
project, its progress and achievements in plain and sci-
entific language, press releases and announcements of
and registration for conferences and training events. Ex-
ternal evaluation of dissemination plans, including the
identification of successful implementation strategies
and barriers to implementation among end users (e.g.
PTSD sufferers, health service planners and managers,
clinicians, clinical professional bodies, etc.) will be
undertaken by the TSC.
Discussion
Strengths of the study
This will be the first study to compare GSH for PTSD to
a face-to-face therapy and will provide valuable informa-
tion on which the NHS can make decisions about its
suitability for use. The GSH intervention under investi-
gation has been rigorously designed and tested and
shown to be effective in pilot work. The study team are
highly experienced in PTSD research and include the de-
signers of TFCBT and GSH interventions, and the trial
is being co-ordinated by an experienced Clinical Trials
Unit (Centre for Trials Research, Cardiff University) with
thorough Standard Operating Procedures. They will
oversee rigorous data collection through the use of an
electronic database designed to minimise missing or in-
accurate data. The trial is multi-centre across England,
Scotland and Wales and will be trialled in the services it
would be delivered in if adopted by the NHS, thus en-
suring its applicability to real life. The therapists have re-
ceived thorough training and supervision in both
TFCBT and GSH, and adherence to the protocol man-
uals will be checked by fidelity assessors. In addition, the
assessors will use the CAPS-5, the ‘gold standard’, to
measure PTSD symptoms and have all received training
and feedback in using this assessment. Finally, a patient
representative has been involved in all stages of the
design of the study, has reviewed the GSH intervention
and participant materials and sits on the Trial Manage-
ment Committee.
Challenges
This will be a pragmatic study conducted in a real-world
NHS setting. Whilst this offers advantages in terms of
applicability, it can also present unique challenges which
can be broadly classified into three categories. The first
is participant recruitment, retention and adherence. We
know that people with PTSD can experience high anx-
iety and may at times find it difficult to leave the house,
use public transport or travel to new places. This could
mean a reluctance to take part or missed appointments,
making it difficult to deliver the interventions as
intended. This is particularly the case for the South
Wales participants from two health boards who will
be travelling considerable distances to Cardiff for
treatment. This will be addressed with participants
before they are randomised, to ensure ability to fully
commit to the study.
Secondly, therapist retention may be a challenge. All
therapists delivering the interventions are NHS em-
ployees with high caseloads, and taking part in the re-
search is an additional responsibility. As such, there may
be times when it is difficult for them to attend the study
specific supervision sessions or site initiation visits, and
the research team will need to be flexible in terms of de-
livering these. If a therapist does need to drop out of the
study due to other work commitments or for personal
reasons, it will not be a quick process to replace them,
given the training requirements. Therefore, we plan to
train several therapists at each site to minimise the risks
of a site needing to close to recruitment. This also ap-
plies to assessors: several of our assessors are employed
by the CRN and therefore we are subject to them being
able to provide ongoing support.
Thirdly, there may be issues around the fidelity of the
delivery. The therapists in the study have prior training
in additional therapies and may bring elements of these
into their sessions with participants. Conversely, they
may not utilise all the tools available in TFCBT or GSH.
To assess fidelity to the intervention, therapists have
been asked to audio record at least one session from
every participant. Whilst this would ideally have been
every session, the limited availability of costly encrypted
audio recorders meant this is not feasible.
All of these potential challenges will be thoroughly
evaluated in the process evaluation.
Conclusion
In summary, previous work has shown that trauma fo-
cused online GSH has the potential to be an effective
treatment for PTSD. No study to date has compared
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GSH to face-to-face therapy. This study will be the first
to compare the two, thus allowing the NHS and other
health services and professionals to make decisions
about the suitability of GSH as a treatment option. The
study’s strengths are that it is led by a highly experienced
team of PTSD researchers in conjunction with a trials
unit and is conducted in a real world setting, thus ensur-
ing it is applicable to the intended recipients. The chal-
lenges will be participant recruitment, retention and
adherence, therapist retention and fidelity of interven-
tion delivery.
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